RespireRx Pharmaceuticals Inc. is a biopharmaceutical company focused on developing groundbreaking treatments for disorders caused by disruptions in neuronal signaling. The company operates in the healthcare and pharmaceutical market, primarily targeting conditions such as spinal cord injury and attention deficit hyperactivity disorder (ADHD). RespireRx's core products include AMPAkines and GABAkines, which are neuromodulators designed to enhance the function of specific neurotransmitter receptors in the brain. These compounds aim to improve neuronal communication without the severe side effects associated with earlier generations of similar drugs.

RespireRx serves a diverse range of clients, including healthcare providers, research institutions, and patients suffering from neurological disorders. The company's business model revolves around the research, development, and commercialization of its proprietary compounds. Revenue is generated through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.

Keywords: biopharmaceutical, neuronal signaling, AMPAkines, GABAkines, spinal cord injury, ADHD, neuromodulators, healthcare, pharmaceutical, innovation.